Trophos to Lead new MitoCare Consortium Awarded EUR 6 Million to Study Cardioprotective Compound, TRO40303
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Trophos SA, announces a European Union award of EUR 6 million to support MitoCare, a 2.5 year international, translational medicine project. MitoCare, which will begin in January 2011, will be conducted by a 16 partner consortium and led by Trophos.
MitoCare forms part of the Seventh Framework Programme of the European Community for Research, Technological Development and Demonstration Activities (FP7). MitoCare will investigate the efficacy and safety of TRO40303 in a phase 2 study to treat cardiac ischemia-reperfusion injury (IRI) in acute myocardial infarction (MI) patients and develop knowledge of biomarkers and models of cardiac ischemia-reperfusion injury.
“We are proud the European Union, after extensive expert evaluation, has chosen to support the MitoCare project and Trophos is very pleased to be collaborating with a distinguished panel of clinical, academic and SME partners,” said Damian Marron, Trophos’ CEO. “There are around 1.6 million cardiac reperfusion procedures performed in hospitals and specialist clinics each year in the western world alone. This program fits perfectly with Trophos’ strategy of creating value by targeting niche, high medical need markets. Cardiac reperfusion injury is a significant unmet medical need with no existing treatment that contributes to long-term morbidity, progression to heart failure and death following a MI.”
“Trophos is excellently positioned to deliver on its goals with this program as well as with our lead product, olesoxime, in a phase 3 study for the orphan neurological disease of amyotrophic lateral sclerosis as part of another EU funded project, MitoTarget,” added Damian Marron.
MitoCare forms part of the Seventh Framework Programme of the European Community for Research, Technological Development and Demonstration Activities (FP7). MitoCare will investigate the efficacy and safety of TRO40303 in a phase 2 study to treat cardiac ischemia-reperfusion injury (IRI) in acute myocardial infarction (MI) patients and develop knowledge of biomarkers and models of cardiac ischemia-reperfusion injury.
“We are proud the European Union, after extensive expert evaluation, has chosen to support the MitoCare project and Trophos is very pleased to be collaborating with a distinguished panel of clinical, academic and SME partners,” said Damian Marron, Trophos’ CEO. “There are around 1.6 million cardiac reperfusion procedures performed in hospitals and specialist clinics each year in the western world alone. This program fits perfectly with Trophos’ strategy of creating value by targeting niche, high medical need markets. Cardiac reperfusion injury is a significant unmet medical need with no existing treatment that contributes to long-term morbidity, progression to heart failure and death following a MI.”
“Trophos is excellently positioned to deliver on its goals with this program as well as with our lead product, olesoxime, in a phase 3 study for the orphan neurological disease of amyotrophic lateral sclerosis as part of another EU funded project, MitoTarget,” added Damian Marron.
